Aligos Therapeutics Inc ALGS.OQ ALGS.O is expected to show a fall in quarterly revenue when it reports results on March 10 for the period ending December 31 2024
The South San Francisco California-based company is expected to report a 78.4% decrease in revenue to $433.33 thousand from $2.01 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Aligos Therapeutics Inc is for a loss of $2.50 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Aligos Therapeutics Inc is $67.50, above its last closing price of $13.48.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -2.47 | -2.16 | -3.07 | Missed | -42.3 |
Jun. 30 2024 | -4.00 | -4.00 | 0.80 | Beat | 120 |
Mar. 31 2024 | -4.75 | -4.75 | -5.50 | Missed | -15.8 |
Dec. 31 2023 | -2.75 | -6.75 | -5.50 | Beat | 18.5 |
Sep. 30 2023 | -11.73 | -11.87 | -10.25 | Beat | 13.7 |
Jun. 30 2023 | -12.19 | -12.37 | -10.75 | Beat | 13.1 |
Mar. 31 2023 | -11.93 | -12.12 | -13.25 | Missed | -9.3 |
Dec. 31 2022 | -11.45 | -11.80 | -12.75 | Missed | -8.1 |
This summary was machine generated March 7 at 12:44 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。